News
The six best period tracking apps for 2025
Period tracking apps have become a cornerstone of the femtech revolution, with more than 50 million women worldwide now monitoring their cycle each month. Here’s six top-rated menstrual health apps to simplify your search.
Beyond just predicting your period, these apps can offer valuable insights into your body, help manage symptoms, and even flag potential health concerns.
Tracking your cycle empowers you with knowledge about your ovulation and fertility windows. If you’re planning a pregnancy or practicing birth control, knowing these patterns can be a game-changer.
Many people experience shifts in mood, energy, and physical well-being throughout their cycles, logging these patterns can allow you to anticipate symptoms better and take steps to reduce their impact.
Changes or irregularities in your cycle can also point to underlying health conditions like hormonal imbalances, thyroid issues, or PCOS. While they aren’t a replacement for medical advice, tracking your cycle can alert you to something that’s not quite right.
However, as demand for these products has increased, so has the number of apps coming to market. In 2023, the global menstrual health apps market was valued at USD 1.87 billion and a quick search of the app store brings up dozens of different options. So how do you know which one is right for you?
We’ve curated a list of six top-rated period tracking apps to simplify your search.
Nexus
Nexus isn’t just a cycle tracker, it’s a holistic women’s health coach which includes a cycle tracker but also nutrition, exercise and more to give you a more comprehensive experience when engaging with Nova, your AI coach
Nexus bridges this gap with a female-specific onboarding process offering over 50,000 unique combinations of personalised wellness insights.
With Nova, users also have access to an AI coach that truly knows them, offering adaptive, actionable guidance grounded in science and tailored to each woman’s unique physiology and life stage.
The vision behind Nexus is to give women control over their own health data, using it to improve conversations with healthcare providers, reduce medical gaslighting and accelerate diagnosis times through advocacy and education.
At the heart of Nexus lies a proprietary large language model (LLM) and peer-reviewed health database, built specifically for women.
This architecture blends medical research, clinical guidelines and user data to generate precise recommendations, far surpassing the capabilities of off-the-shelf AI systems.
- Built by medical professionals and scientists. Our team of experts have built, reviewed and tested this product.
- AI-powered health coach Nova, built from scratch to handle the bias and hallucinations for women’s health with AI
- Personalized experience: Nexus adjusts predictions and recommendations to each user’s unique cycle and health characteristics.
- Nexus is free with no upsales or features behind the pay wall.
- 5* reviews in the App Store.
- Your data is private. We don’t share your personal data with the AI model or any 3rd parties.
Nexus is only available on the UK Apple app store currently. You can download the app here or join the international / Android waitlist here. Coming early 2026.
Femia app
Femia is a fertility and pregnancy tracking app with a mission to empower women with knowledge about their bodies, making their fertility journey more personalized and smooth. Femia is supported by cutting-edge AI and provides outstanding support for period and ovulation tracking, helping over 35,000 users achieve their dream of conceiving by mid-2024.
Femia app combines science-backed tools with an intuitive design and nice animations to provide a top-notch experience for all users. With its effortless cycle tracking, the app predicts ovulation and menstrual phases with remarkable precision. Users can log various symptoms like mood changes, vaginal discharge, and physical activity to receive tailored insights that help identify fertile windows or early pregnancy signs.
For those planning a pregnancy, Femia’s Fertility Card highlights key cycle dates directly on the Home screen, simplifying family planning. Since early 2024, Femia has included a Pregnancy Mode to continue journey with those users who got pregnant. It allows moms-to-be to easily monitor their health, track their baby’s growth and development, and receive personalized health tips at every stage of pregnancy.
What sets Femia apart:
- Science-backed and expert-reviewed: All content is curated by OB/GYNs, fertility specialists, psychologists, and fitness experts.
- AI-powered health assistant (Mia): Available 24/7, Mia answers fertility questions and guides users through each cycle or pregnancy phase, based on the user’s logged symptoms, ensuring relevant information is always at hand.
- Personalized experience: Femia adjusts predictions and recommendations to each user’s unique cycle and health characteristics.
- Global trust: With over 1.4 million downloads worldwide, Femia supports users in 10+ languages, with Spanish speakers making up 16% of its base.
- Budget-friendly: Femia brings powerful features at a price that fits your budget. With flexible pricing, you get high-quality performance without the high costs.
- Unwavering data privacy: Femia ensures your personal information is secure, providing peace of mind.
Loved by users across platforms, Femia App is rated 4.9 stars on the App Store and 4.7 stars on the Play Market. Whether you’re tracking your cycle, planning a pregnancy, or monitoring your pregnancy journey, Femia delivers exceptional value and insight every step of the way.
Discover the future of fertility tracking—Try Femia today!
Stardust
Founded and built by women, Stardust is the ultimate cycle-informed health tracker that helps you truly understand your body in a whole new way. Combining period, hormone, and pregnancy tracking with modern science and ancient wisdom like lunar syncing, Stardust offers a complete view of how your cycle shapes your overall well-being. Unlike traditional trackers that focus only on ovulation, Stardust gives you personalized insights that go beyond predictions, diving deeper into every phase of your health journey.
What makes Stardust stand out? It’s the only tracker that lets you share your cycle with friends and follow theirs too, creating a supportive community around your health. Plus, the partner version helps keep your partner in the loop with phase-specific updates, so they can support you through every phase. With integrations like Oura, your everyday data becomes a source of wonder, revealing hidden patterns and connecting the dots between your cycle, sleep, energy, and more.
Stardust is free to download, offering an easy and insightful way to stay in tune with your body, whether you’re tracking your period, planning a pregnancy, or navigating the journey to parenthood. With secure data encryption, Stardust is setting a new standard for body literacy, empowering you to make informed decisions every day.
luna
luna is on a mission to be the go-to digital health and wellbeing companion for teens throughout adolescence, co-piloting with parents along the way.
By taking a holistic approach to adolescent health, luna empowers teens and their families to navigate the tricky terrain of adolescence together, from understanding periods to tackling skin issues, mental health, and friendship struggles.
On the luna app (search ‘we are luna’ on App Stores), teens can track their periods, moods, sleep, and skin, receiving personalised insights and actionable recommendations tailored just for them. They also have a safe space to ask anonymous questions and learn from articles, videos, and quizzes – all verified by a team of doctors and safeguarding experts.
The app also enables parents to gain on-the-pulse insights and advice that’s tailored to the real issues facing teens today. Through a dedicated parenting newsletter, parents receive guidance on everything from social media trends to watch out for, to news stories and how to foster open, meaningful conversations.
With luna, parents and teens don’t just co-exist through the ups and downs of adolescence – they thrive together. The app equips teens with tools to understand their bodies, build confidence, and reach out for support when needed – the first of its kind. At the same time, parents are empowered with resources to guide and support their teens through their formative years.
Other member benefits include exclusive discounts through partnerships with aligned health and wellbeing brands, such as Gymshark, free access to webinars run by adolescent experts, plus so much more.
Whether you’re a parent looking to find out what teens of today are really thinking about, or a teen in need of advice and empowerment, sign up to luna and discover how it can help you.
luna is so much more than a tracker – it’s a female-founded community and an absolute necessity to help both parents and teens thrive through adolescence.
Learn more at weareluna.app or sign up for the parenting newsletter here.
Clue
Clue is a Berlin-based, women-led menstrual and reproductive health app that harnesses the power of full cycle intelligence to help you understand your body’s inner workings, beyond bleeding.
What do people who use Clue love the most? No pink. No myths. And no taboos. Clue is an intuitive, science-based, data-driven cycle health tracker with 100+ different tracking options and a powerful algorithm to help you live a life more in sync with your full cycle – not just to predict your period (although it does that too!).
Loved by over 10 million monthly active users across 190+ countries, and available in 20+ languages, the Clue app intuitively guides you through each cycle, change, and choice. From general cycle health awareness and education to fertility, pregnancy, and even navigating perimenopause.
New in 2024, is Clue’s My Health Record feature which uses de-identified data for good, to help close the diagnosis gap for female health conditions.
You can enter confirmed diagnoses for up to 21 different health conditions including endometriosis, polycystic ovary syndrome (PCOS), premenstrual dysphoric disorder (PMDD), uterine fibroids, bleeding disorders, anxiety disorders, and more. With this feature, the Clue community is collectively building an unprecedented dataset linking confirmed diagnoses and tracked cycle data to enable impactful research on the most commonly misdiagnosed and under-researched female health conditions.
The Clue app is free to download and you can unlock deeper insights and additional personalised modes like Clue Conceive, Clue Pregnancy, and Clue Perimenopause with the premium subscription, Clue Plus.
For more, visit helloclue.com.
Premom blends period tracking with powerful ovulation and hormone insights—ideal for anyone who wants to get in sync with their body or is actively trying to conceive.
What makes Premom different? It combines detailed hormone tracking with an AI-powered algorithm that learns from your unique data.
By logging ovulation test results (with digital test reading), basal body temperature (BBT), cervical mucus, you help Premom predict your ovulation and period with greater accuracy—even if your cycles are irregular.
The app includes a simple period and ovulation calendar, plus automatic BBT and ovulation charting, making it easy to spot your fertile window, hormone patterns, and cycle shifts—all in one smart, easy-to-read chart.
Developed by the makers of Easy@Home ovulation tests, over 1 million users have gotten pregnant while using the Premom app*.
Not wanting to wait any longer to conceive? FastPass™ to Pregnancy offers a clear, guided plan to help you get pregnant faster—with smarter ovulation predictions, weekly expert check-in videos, and personalised cycle tips, all backed by data.
Need help interpreting your results or deciding what to do next? Fertility AI Pro gives you personalised, real-time responses based on your hormone test results and logged cycle data—so you’re never left guessing.
Premom also includes a Pregnancy Mode, offering weekly development and body change updates, symptom tracking, and expert tips to support you through every trimester.
And with the Predad™ feature, partners can get synced up, too—giving them insights and tips to be more involved and supportive from conception thru pregnancy.
Want even more support?
Premom Premium unlocks advanced reports, webinars led by fertility experts, and extra tools like a PCOS self-assessment to help you feel more informed and empowered throughout your reproductive journey.
The Premom app is free to download, with the optional upgrades for added support.
Learn more at www.premom.com.
*Over 1 million users logged pregnancy or positive pregnancy test results while using the Premom App
Women later diagnosed with endometriosis used more antidepressant and anxiety medication than other women, with the pattern emerging years before diagnosis, recent study found.
The difference was evident up to 10 years before diagnosis and continued for a decade afterwards, according to a large Danish registry-based study involving 136,842 women.
Women with the condition also had substantially more contact with psychiatric hospital departments than those without it.
Researchers at Aarhus University found that women with endometriosis redeemed 29 per cent more prescriptions for antidepressants and 16 per cent more for anxiety medication in the years before diagnosis.
After diagnosis, the differences rose to 40 per cent for antidepressants and 46 per cent for anxiety medication.
Marie Josiasen, PhD student at the department of public health and one of the researchers behind the study, said: “What surprised us was how clear and persistent the pattern was, and that the difference did not diminish over time.
“On the contrary.
“Women with endometriosis consistently redeemed more prescriptions for antidepressant medication than women without the disease throughout the entire period, from ten years before to ten years after diagnosis.”
The study does not provide an answer as to what causes the mental strain.
Josiasen said prolonged pain, uncertainty about the cause of symptoms and fertility problems could be among the factors contributing to psychological strain.
She said: “It’s possible that prolonged pain, uncertainty about the cause of the symptoms, and frustration over not being able to live the life one wants may be among the reasons. For some women, fertility problems can also be a major psychological burden.”
Researchers also found that the gap compared with women without endometriosis did not narrow after diagnosis. Instead, it became more pronounced in the years that followed.
Josiasen said: “A diagnosis can be a relief, but it also involves coming to terms with having a chronic illness.”
The study does not indicate whether diagnosing endometriosis earlier could reduce psychological strain.
As part of her PhD project, Josiasen will investigate the role hormonal contraception may play in the mental health of women with endometriosis.
She said: “We can see that many receive medication and are in contact with psychiatric services. But we still lack an understanding of what actually helps these women.
“That’s what I want to help find out.”
Calla Lily Clinical Care has joined a US$50m antibiotics programme to assess vaginal delivery of UTI treatments through its Callavid platform.
The women’s health medical technology company will evaluate whether antibiotics can be delivered directly through the vaginal wall to treat urinary tract infections (UTIs).
The project will use Callavid, the company’s intravaginal drug delivery platform, aiming to deliver treatment to the site of infection while limiting systemic exposure.
Calla Lily has been selected for Wellcome Leap’s Focused Antibiotics programme, which is exploring ways to reformulate existing antibiotics so they reach infections while sparing the gut microbiome without loss of efficacy.
Dr Serena de Gelidi, Principal Investigator and R&D Manager, Calla Lily Clinical Care
The programme is backed by US$50m and aims to investigate technologies that could reduce the unintended effects of antibiotic treatment.
UTIs are among the most common bacterial infections in women. According to the source material, women are prescribed almost 40 per cent more antibiotics than men between the ages of 16 and 54.
Calla Lily will assess whether Callavid can deliver antibiotics through the vaginal wall while bypassing gastrointestinal transit and first-pass metabolism.
The company expects the approach could keep systemic exposure below 5 per cent.
There is currently no first-line UTI antibiotic available in a mass-manufactured vaginal formulation, according to Calla Lily.
The company said a successful project could contribute to the wider programme’s goal of reducing antibiotic-driven resistant infections by up to 40 per cent a year.
Callavid has a patented, leak-free, tampon-like design intended to deliver medicines and hormones through the vagina.
The platform is already being assessed in the NIHR-funded FREEDOM trial, which is studying vaginal progesterone delivery using Callavid.
That study began in April 2026 and is examining safety, user acceptability and drug absorption. According to the company, it has passed its safety stopping rule and 90 per cent of patients have completed their first round of dosing.
Dr Lara Zibners, co-founder and chair of Calla Lily Clinical Care, said: “Women are disproportionately impacted by urinary tract infections, yet the consequences of that repeated systemic exposure have been largely overlooked. Organisations such as Wellcome Leap play a vital role in tackling major healthcare challenges through bold innovation. We are honoured to be part of the Focused Antibiotics programme and to explore the potential of Callavid in a foundational antibiotic application, demonstrating how women’s health innovations can deliver benefits far beyond fertility and reproductive care.
Thang Vo-Ta, co-founder and chief executive of Calla Lily Clinical Care, said: “Being selected by Wellcome Leap, one of the world’s most ambitious health innovation funders, is a significant validation of what we are building at Calla Lily Clinical Care. Our ambition has always been for Callavid to become the defining platform for intravaginal drug delivery across a wide range of indications. The Focused Antibiotics programme gives us the ideal partner to pursue one of the most consequential of those indications: treating the world’s most common bacterial infection in women while helping to address a global resistance crisis that, left unchecked, could claim eight million lives annually by 2050. This marks a pivotal moment in demonstrating that when you solve for women, you solve for everyone.”
The project will be led by Dr Serena de Gelidi, principal investigator and R&D manager at Calla Lily Clinical Care.
She will be supported by Professor Andrew Lewis, principal scientist at the company and an international authority on drug-eluting systems, with 58 patents and more than 260 peer-reviewed publications.
An AI tool has identified microscopic breast cancer patterns that could help medical professionals better forecast disease progression.
The tool, called CenSegNet, was developed to analyse hundreds of thousands of cells in tumour samples and detect abnormalities in structures known as centrosomes.
Centrosomes are small structures inside cells that ensure DNA is divided equally during cell replication. Researchers say abnormalities in these structures have been considered a hallmark of cancer for more than a century.
In cancerous tissue, centrosomes can replicate excessively, driving the progression of the disease.
Scientists at the University of Southampton used the system to study tissue from 127 breast cancer patients being treated at University Hospital Southampton.
More than 330,000 centrosomes were analysed, revealing two distinct abnormalities that had previously been considered part of the same process.
One involved cells developing too many centrosomes, while the other involved centrosomes becoming abnormally enlarged.
Researchers found the two defects behaved independently and could occur in different areas of the same tumour.
Dr Salah Elias, of the University of Southampton’s school of biological sciences and institute for life sciences, said: “For more than a century, centrosome abnormalities have been recognised as a hallmark of cancer, but studying them in patient tissues has been extremely challenging.
“CenSegNet allows us to analyse these defects at single-cell resolution across entire tumours and uncover patterns that were previously impossible to see.
“Rather than viewing centrosome abnormalities as a single phenomenon, our study shows that they have distinct biological states with different spatial distributions and clinical associations.”
The platform also helped uncover a link between different centrosome abnormalities and features of cancer.
Tumours with high levels of enlarged centrosomes were more aggressive, while patients whose cells had lower levels had a better chance of survival.
Dr Elias said: “Specific combinations of defects may influence how a tumour grows, invades surrounding tissues and responds to treatment.
This opens the door to developing new biomarkers and, ultimately, more personalised treatment strategies.”
Researchers hope AI could eventually be used to track disease by analysing the behaviour of cell structures.
The team also plans to combine CenSegNet with more data to explore whether it could help guide treatment decisions.
News2 weeks agoUK femtech investment surges 194% in a decade, research finds
Entrepreneur2 weeks agoTidalSense raises £14m to expand five-minute COPD test across NHS
News2 weeks agoCross-Border Impact Ventures raises US$58m for women and children’s health
Insight2 weeks agoWomen urged to be wary of menopause misinformation on social media
Entrepreneur7 days agoApplications close August 18 for Women’s Health Innovation Summit 2026 Innovation Showcase
Menopause2 weeks agoCultural stigma is a barrier to menopause help, black women say
Mental health7 days agoThird of women unaware of perimenopause mental health impact
Motherhood2 weeks agoOne in eight mothers diagnosed with gestational diabetes, research finds
4 Comments